“In addition to the cited drug claims, you market bacteriostatic water as a solvent for reconstituting your products, thus, providing the means to prepare an injectable drug for human administration.”U.S. Food and Drug Administration, warning letter to Peptide Partners LLC · Aug. 24, 2026
Sources: FDA warning letter to Peptide Partners LLC, Sarasota, Fla., dated Aug. 24, 2026, posted Sept. 1, 2026; FDA letters of March 31 and June 17, 2026 to other sellers; Investing News Network, Feb. 11, 2026, citing Grand View Research.
Nobody on the Sarasota website was selling semaglutide. They were selling “GLP-1 S.” Not tirzepatide, “GLP-2 T.” Not retatrutide, “GLP-3 Reta.” The codenames are the first tell. A licensed pharmacy calls a drug by its name because the name is on the prescription. A copycat calls it something else because the name would be a claim, and claims are what the FDA regulates.
The rest of the disguise is standard. “For research use only” on the vial. “Not for human or veterinary use” in the footer. A checkbox at checkout agreeing that you are a laboratory. And, three clicks away, a bottle of bacteriostatic water labeled “Reconstitution Solution,” which exists for exactly one purpose: turning a powder into something you can inject.
The FDA’s letter, dated August 24 and posted September 1, is the agency saying out loud what every customer already knew. The product pages talked about “powerful effects on weight loss and blood sugar control.” Nobody was doing research. The costume came off. What is left is a question for the person who was about to buy: which kind of copy were you looking at, and is there a kind that is actually legal?
Not a copycat. A prescription.
Refills GLP-1s are prescribed by licensed clinicians and compounded by licensed, state-inspected U.S. pharmacies, then shipped free to your door with your name and dose on the label. From $5/day, the same price at every dose, no membership fees, cancel anytime. A 40%-off offer is live right now.
2-minute intake · Clinician review often within hours · Prescription required · Compounded, not FDA-approved
Three Kinds Of Copy
Every non-brand GLP-1 in America is one of three things. Sellers make a living on people not knowing which.
The counterfeit
Pretends to be the brand. A pen or carton dressed as Ozempic, Wegovy or Mounjaro that Novo Nordisk or Eli Lilly never made. The FDA has seized these from inside the legitimate U.S. supply chain three times since 2023, once with needles whose sterility “cannot be confirmed.”
Priced like a discount on the brand · is not the brand
The “research” formula
Pretends to be a chemical. Powder in a vial with a codename and a “not for human use” sticker, sold with the water and syringes to use it on a human. No prescriber, no pharmacy, no patient on paper. This is the Sarasota model, and the FDA has now sent at least 13 of these letters this year.
$60–$200 a vial · you are the pharmacist
Compounded, under a prescription
Does not pretend. A licensed clinician reviews you and prescribes. A state-licensed, state-inspected U.S. compounding pharmacy prepares that prescription and puts your name and dose on the label. Called by its real name. Not FDA-approved, not the brand, and the honest providers print that sentence where you can read it.
At Refills: from $5/day · same price at every dose
The first two share a business model: the seller’s protection comes from the label. “Not for human use” means that when something goes wrong, the paperwork says you misused a research chemical. The third has the opposite model. The pharmacy’s name is on the vial because the pharmacy is accountable for what is in it.
The legal copy, from $5/day: see Refills’ pricing →
What The Loophole Buys The Seller, And What It Costs You
The “research use only” label is not a legal shield so much as a delay. It worked for years on obscure peptides because nobody was looking. It is failing now because semaglutide is not obscure, and because the FDA found a simple test: does the site also sell the means to inject it? The Sarasota letter cites the water. Other letters cite the syringes, the dosing guides, the testimonials.
But notice what the letter does not do. It does not recall the vials. It does not notify the customers. It gives the company fifteen business days to respond and warns of “seizure and injunction” if it does not. Everyone who bought before September 1 still has their powder, their water and their spreadsheet, and nobody is coming to check on them.
That is the real cost of the loophole. It transfers every job a pharmacy does onto the buyer:
A pharmacy knows what is in the vial because it made it from tested ingredients under a batch record. You know what the website said. The FDA has an import alert on GLP-1 raw ingredients “with potential quality concerns” for a reason.
You add the water, so you set the concentration. Get the arithmetic wrong and the FDA has your case already: doses five to twenty times too high from people confusing units, milliliters and milligrams.
A pharmacy compounds under a hood in a room a state Board of Pharmacy inspects. Injected drugs, the FDA wrote, “bypass some of the body’s key defenses against toxins and microorganisms.” Your kitchen is not inspected.
Nobody asked about your thyroid, your pancreas, your other medications or a pregnancy. Nobody can say no. The site’s position, in writing, is that you are not a patient.
Let the pharmacy do the pharmacy’s job.
Refills connects you with licensed clinicians who review your health history and decide, independently, whether a compounded GLP-1 is appropriate. If it is, a licensed U.S. compounding pharmacy prepares it, labels the dose, and ships it free in plain packaging.
GLP-1s from $5/day · All dosages at the same low price · No monthly memberships or app fees · 40% off running at the time of writing
Why Americans Keep Clicking
Because the alternative they were shown was a four-figure pen. Wegovy lists at $1,349 a month, Zepbound at $1,086, Ozempic at $1,028. The manufacturers’ own cash programs cut that to $199 to $449 a month depending on dose, and both now sell a pill from about $149. Real prices, real products, and still $2,400 to $5,400 a year for as long as you stay on.
Meanwhile roughly 12% of American adults have used one of these drugs, employer coverage fell from 72% to 60% in a year, and several state Medicaid programs stopped paying for them in January. A copycat site with a $79 vial and 4.8 stars is not competing with a pharmacy. It is competing with going without.
Britain, which is a year or two ahead of the U.S. on this curve, seized 5,851 fake or unlicensed weight-loss injections in 2025, up from 407 in 2023. One study there found one in seven users taking a product not licensed for weight loss, “often purchased privately.” The Sarasota site was not an outlier. It was the market.
Five Questions That Unmask A Copycat
- Does it call the drug by its name? Semaglutide, tirzepatide. A codename, an abbreviation or a nickname is a seller avoiding a claim. There is no legitimate reason to sell “GLP-1 S.”
- Can you buy it without anyone saying yes? If a GLP-1 goes into a cart after a quiz, or with no questions at all, there is no prescription and no pharmacy, whatever the site is called.
- Does the label say “not for human use”? Then the seller has told you who is protected if something goes wrong. It is not you.
- Do they sell the water and the syringes? That is the exact evidence the FDA used to prove the “research” story was fiction.
- Do they offer retatrutide? No pharmacy on earth can dispense it. A seller who has it is telling you which kind of copy they sell.
How Refills Answers Those Five
Refills’ own published terms, quoted as they appear on the site, so you can hold them to it.
Refills offers compounded GLP-1s, called what they are, with the sentence printed on the site: “Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Prescription required.” No codenames, no “generic Ozempic.”
“Refills connects you with licensed clinicians who review your health intake, follow established protocols, and make independent clinical decisions.” Review often within hours. Refills is a technology platform, not a medical provider: the clinician decides, and can decide no.
“Exclusively from U.S. pharmacies,” which “are licensed and inspected by Boards of Pharmacy.” Refills does not manufacture or dispense medication; the pharmacy does, with your name on the label.
The pharmacy prepares and labels the dose under your prescription. Instructions come from the pharmacy and your clinician. A free 24/7 Health Concierge answers questions before you inject. LegitScript certified, the same certification Google requires before a telehealth provider can advertise.
“GLP-1s from $5/day.” “All dosages at the same low price. We don’t charge you based on dosage changes.” “Never pay for monthly memberships or app fees.” Free discreet shipping; pause, skip or cancel from the dashboard. A 40%-off offer on GLP-1 plans is live at the time of writing. Available in all 50 states, not the District of Columbia.
Two minutes. Then a clinician decides.
Health history, goals, current medications. No insurance card. A licensed provider reviews it, often within hours, and if a compounded GLP-1 is appropriate, a licensed U.S. pharmacy ships it to your door.
From $5/day · Same price at every dose · Free discreet shipping · Cancel anytime
What The Medication Actually Does
GLP-1 medications work on appetite signaling. People describe it the same way over and over: the food noise gets quieter, they feel full sooner, and the late-night pantry stops being an argument. That is why so many people who “failed” diet after diet were never the problem. The mechanism was.
What the trials of the FDA-approved products showed. In the STEP 1 trial (68 weeks), adults on semaglutide 2.4 mg lost an average of 14.9% of body weight versus 2.4% on placebo. In SURMOUNT-1 (72 weeks), adults on tirzepatide lost an average of 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg, versus 3.1% on placebo.
Those trials studied Wegovy and Zepbound, the FDA-approved products, not compounded medications, which have not been evaluated by the FDA and were not studied in these trials. They are not Refills customer results. Individual results vary.
None of those trials studied “GLP-1 S” either. The copycat borrows the brand’s science and none of its accountability.
How It Works At Refills
Health history, goals, current medications. About two minutes. No insurance card, no waiting room.
A licensed provider reviews your intake, often within hours, and makes an independent decision. If it’s a no, that’s the answer.
If prescribed, a licensed U.S. compounding pharmacy prepares and labels it. Most orders arrive in 3–5 business days, in plain, unbranded packaging.
Dose changes, if your clinician makes them, do not change the price. There is no membership to unlock the support line. You can message a human without paying for the privilege.
Results People Put Their Name On
Refills publishes customer stories on its site. It also publishes the line most brands bury: results depicted are not typical. On Trustpilot, it holds a 4.0 “Great” TrustScore across 1,398 reviews as of August 2026, most of them about a named human who picked up the phone.
“Refills helped me get my energy back. I feel sharper, stronger, and finally excited to take on each day.”
“Thanks to Refills, I’m sleeping better, moving easier, and feeling like myself again.”
“Refills changed my relationship with food. No crash diets, no guilt, just steady, real progress.”
“Refills made it easy and sustainable.”
Results depicted are not typical. Individual results may vary based on starting weight, adherence to treatment, diet, exercise, and other factors. Stories are self-reported by users under clinician supervision, as published at refills.com.
Who This Is For, And Who It Isn’t
It is for the person who has a “research peptides” tab open right now and just noticed the product is not called by its name. It is for the person who already bought one and has been uneasy about it since.
It is not for someone whose insurance covers the brand pen; use that. It is not a way to get retatrutide, which no one can legally sell. And it is not a way around a clinician. One still has to say yes.
If that’s you: start the intake at Refills →
The Questions People Ask After The Headline Wears Off
Isn’t a compounded GLP-1 also a copy?
It is a version of the same active ingredient, prepared by a licensed pharmacy under a prescription and labeled as what it is, which is what makes it legal. It is not FDA-approved, and Refills says so on its site. The two illegal kinds of copy pretend to be something else: the brand, or a chemical. The legal kind does not pretend.
Is this Ozempic or Wegovy?
No. Ozempic, Wegovy, Zepbound and Mounjaro are FDA-approved brand-name products. If a Refills clinician prescribes, the medication is a compounded GLP-1 prepared by a licensed U.S. compounding pharmacy, a different regulatory category.
I already bought a “research” vial. What now?
Do not inject it. There is no way for you to verify what it is or how concentrated it is. If you already have and feel unwell, call Poison Control at 1-800-222-1222. Then start over through a route where someone is accountable.
Do I need insurance?
No. The intake and clinician review are designed to work without it.
Does the price go up when my dose does?
Refills says no: all dosages at the same low price, and no charge based on dosage changes. Confirm it at checkout.
How fast does it arrive?
Clinician review often happens within hours. Most orders arrive within 3–5 business days after approval and pharmacy processing, in plain packaging, no signature required.
Where is Refills available?
All 50 states. Not the District of Columbia.
“GLP-1 S” is a disguise. This isn’t.
Two minutes on an intake. A licensed clinician looks at your actual history and decides. If it’s yes, a licensed U.S. pharmacy prepares your prescription, calls it by its name, and ships it to your door for a price that doesn’t climb when your dose does.
GLP-1s from $5/day · 40% off live now · Free discreet shipping
The website renamed the drug so it would not have to make a claim. The FDA’s letter made the claim for them. The customers, meanwhile, had been making it all along, one injection at a time.
Disclosures & Sources
This page is a sponsored advertisement for Refills Health. It is not a news report and not medical advice. Product names, quotations and enforcement details are from the FDA warning letter to Peptide Partners LLC, reference 735063, dated August 24, 2026 and posted September 1, 2026, and FDA letters of March 31 and June 17, 2026 to other sellers. Counterfeit-Ozempic details are from FDA’s counterfeit Ozempic alert (entries through Dec. 5, 2025); dosing-error details from FDA’s July 26, 2024 alert. Market and UK figures are from Investing News Network, February 11, 2026, citing Grand View Research and MHRA. Employer coverage figures from the Business Group on Health 2027 survey as reported August 31, 2026. Refills has no connection to any company named in an FDA letter and is cited here only as a contrast. Refills Health is a technology platform that connects users with independent, licensed clinicians through partners such as Beluga Health, Bask Health and Wasef Health. It is not a medical services provider and does not manufacture or dispense medication.
Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Compounding pharmacies are licensed and inspected by state Boards of Pharmacy. Prescription required; a clinician may determine that treatment is not appropriate for you. GLP-1 medications carry risks and side effects; discuss them with your clinician. Results depicted are not typical; individual results vary. Trustpilot quotes are excerpts of public reviews posted by Refills customers in August 2026; TrustScore and review count as displayed on Trustpilot on August 29, 2026.
Brand-name list prices and manufacturer cash-program prices are as published by third-party trackers in June–July 2026 and are subject to change. “Research” vial prices are typical advertised prices observed on such sites in 2026 and are not an endorsement. Clinical-trial figures describe the FDA-approved products studied in those trials, not compounded medications. The hero photograph is illustrative stock and does not depict any product named on this page. Ozempic® and Wegovy® are trademarks of Novo Nordisk A/S; Zepbound® and Mounjaro® are trademarks of Eli Lilly and Company. Neither company is affiliated with or endorses Refills.
